Compare Pinterest Inc (PINS) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pinterest Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Pinterest Inc trades at $22.54 (market cap $12.79B), while Vertex Pharmaceuticals Incorporated trades at $474.2 (market cap $122.33B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 9.6× Pinterest Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Pinterest Inc nearer its low. Which is the better fit depends on your goals.
| PINS | VRTX | |
|---|---|---|
Market Cap | $12.79B | $122.33B |
Sector | Media | Health |
52-Week High | $39.17 | $529.59 |
52-Week Low | $15.42 | $366.54 |
Enterprise Value | $12.69B | $117.07B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pinterest Inc
Pinterest is an online product and idea discovery platform that helps users gather ideas on everything from recipes to cook to destinations to travel to. Founded in 2010, the platform consists of a largely female audience, at roughly two thirds of its more than 365 million monthly active users. The company generates revenue by selling digital ads and is now rolling out more in-platform e-commerce features.
Read more on PINS →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
